Join us for a conversation on the impact of Comprehensive Genomic Profiling (CGP) for patients at the upcoming ISPOR Issue Panel.
Genomic testing is essential for personalised treatment because it matches patients to the most effective treatments based on disease’s molecular profile. CGP tests hundreds of biomarkers in one assay, delivering broader and more precise diagnostics. There is a need for Europe to move beyond small, sequential gene panels toward broader, comprehensive testing that capture the full molecular landscape of cancer and guide treatment decisions more effectively. Yet access to CGP remains limited across Europe.
Join us on the ISPOR Issue Panel to discuss:
- How CGP can transform cancer diagnostics to enable personalised treatments
- What lessons can be learned from national case studies
- The key enablers to make CGP a standard part of cancer care
Speakers:
- Steve Williamson – Associate Director of Managed Access, NICE
- Lucas van Schaik – PhD Candidate, Netherlands Cancer Institute
- Moderated by: Alexander Natz, Secretary General of EUCOPE
📅 Date: Monday, 10 November
🕙 Time: 10:15 – 11:15
📍 ISPOR Issue Panel (Glasgow)
Leave a Reply